Medacta, a Switzerland-based orthopedic device company, is planning an initial public offering, according to Reuters.
Five things to know:
1. So far this year, the Swiss stock exchange added 10 percent and could benefit Medacta's offering.
2. Medacta hopes the IPO will "boost its visibility," according to Reuters.
3. The company hopes to complete the IPO in the second quarter of 2019, as a secondary offering.
4. The Siccardi family, which founded the company, will maintain control.
5. Morgan Stanley and Credit Suisse are serving as the joint global coordinators for the IPO, and JP Morgan and UBS Investment Bank are the joint bookrunners. Medacta's independent financial advisor is Rothschild.